LMAT

LeMaitre VascularD

Nasdaq / Health Care Equipment & Services

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$125.00

+36.4% vs current

Most likely

Base case

50%

Probability

Target price

$111.00

+21.1% vs current

B-

Bear case

25%

Probability

Target price

$94.00

+2.6% vs current

AI sentiment snapshot

Latest data as of 2026-05-08

AI commentary

This is a real earnings-update run, not a SERP-only memo: the company 8-K/Exhibit 99.1 confirms a solid Q1 and somewhat better profit outlook. Even so, the setup remains a tentative monitoring view because deterministic priors remain negative, analyst follow-through is thin, direct peer support is limited, and the stock sat at $107.91 on 2026-05-07 versus the prior baseline price of $117.39 on 2026-04-15 despite the beat. Headline volume is elevated by earnings, but the market reaction argues investors want another quarter of proof before paying up again.

RankAlpha Sentiment Codex - 2026-05-08

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-05catalystQ1 beat with better margin and EPS guidance needs to stabilize the post-print tapeMedium impact

LeMaitre's May 5 earnings release reported Q1 sales of $66.6mm (+11%), gross margin of 72.7% (+350 bps), operating income of $17.8mm (+41%), EPS of $0.68 (+42%), and cash of $367.2mm. Management also guided Q2 sales to $70.5mm-$72.5mm and kept full-year sales at roughly $280mm while guiding full-year operating income to $77.6mm-$82.0mm and EPS to $2.93-$3.08, with commentary that higher ASPs, geographic expansion, and disciplined spending are driving leverage [#8-K-2026-05-05].

2026-06-04eventJune 4 dividend payment and active buyback authorization are modest support, not a thesis resetMedium impact

The same May 5 release announced a $0.25/share quarterly dividend payable June 4, 2026, and reminded investors of the board-authorized $100.0mm repurchase program approved on February 19, 2026, running through February 18, 2027. These capital-allocation tools help downside support, but they do not by themselves resolve whether LMAT can hold a premium multiple after the recent de-rating [#8-K-2026-05-05].

2026-12-31catalyst2026 operating leverage still hinges on Artegraft, pricing, and manufacturing efficiency sustaining through the yearHigh impact

Management highlighted 36% Artegraft growth worldwide, record sales in grafts, valvulotomes, and carotid shunts, geographic records across EMEA, APAC, and the Americas, and gross-margin expansion from higher pricing and manufacturing efficiencies. That is supportive, but the stock still appears to need repeat execution across the rest of 2026 because the revenue outlook was only maintained while the market has already been treating LMAT as a premium growth medtech name [#8-K-2026-05-05].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-08 • Updated nightlySource: Internal modelMethodology